

Χαρακτηριστικά:

- Reviews current pharmacological treatments for Parkinson's Disease, from foundational principles to advanced applications
- Outlines the latest treatment protocols, therapeutic strategies, and emerging trends in Parkinson's Disease pharmacotherapy
- Provides detailed insights into how different drugs operate at the molecular and cellular levels, enhancing comprehension of PD pathophysiology and drug mechanisms
- Presents case studies, clinical trial outcomes, and real-world applications, detailing practical insights applicable to both research and clinical practice

Περιεχόμενα:

Section I: Introduction

1. Parkinson's Disease Pathogenesis: From Molecular Insights to Novel Therapies
2. Cultural and Regional Considerations in Parkinson's Pharmacotherapy
3. The Tango of Parkinson's Treatment: The Dance of Balance and Harmony
4. Environmental Neurotoxins, Circadian Rhythms and Their Pharmacological Antagonists in Parkinson's Disease
5. Oral Bacteriome Dysbiosis and Mechanisms in Cognitive Impairment among Older People and Parkinson's Disease: A Systematic Review

Section II: L-DOPA and DOPAMINERGIC AGENTS

6. Dopaminergic Treatments for Parkinson's Disease: Seeing the Unseen
7. Catechol-O-Methyl-Transferase (COMT) Inhibitors: Present Problems and Relevance of the New Ones
8. D3 Receptor Agonists and Antagonists as Anti-Parkinsonian Therapeutic Agents
9. Non-Dopaminergic Therapies

Section III: EMERGING DRUGS AND TARGETS FOR PARKINSON'S DISEASE

10. Management of Motor Symptoms
11. Non-Motor Symptoms and Their Pharmacological Management
12. Pharmacokinetics and Pharmacodynamics in Parkinson's Disease
13. Clinical Case Studies and Practical Applications
14. Epigenetic Modulators: Emerging Players in Parkinson's Pharmacotherapy

Section IV: FUTURE THERAPEUTIC POSSIBILITIES

15. Emergent Therapeutic Agents in the Treatment of Parkinson's Disease
16. Future Directions in Parkinson's Disease Pharmacotherapy
17. Pioneering The Next Generation Of Therapies
18. Genetic Therapies for Parkinson's Disease: The Dawn of Precision Medicine
19. The Gastrointestinal Microbiota and Parkinson's Disease: What is known and what is

still unknown.

- 20. Artificial Intelligence and Machine Learning in Parkinson's Drug Development
- 21. Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunct to Pharmacotherapy in Parkinson's Disease

Section V: PHARMACOTHERAPY: HOPES AND HYPES

- 22. Neuroprotective Therapies in Parkinson's Disease
- 23. Polypharmacy and combination therapies in Parkinson's Disease
- 24. Repurposing Existing Drugs for Parkinson's Disease Management
- 25. Personalized Medicine and in Parkinson's Disease: Bridging Research and Practice
- 26. Neuroprotective Diets and Their Synergy with PD Pharmacotherapy
- 27. Natural products in the management of Parkinson's disease in animal models

Section VI: COGNITIVE ENHANCERS AND PD PHARMACOTHERAPY

- 28. Cognitive Enhancers in Parkinson's Disease
- 29. Emerging Targets for Cognitive Enhancement
- 30. Artificial Intelligence in PD Pharmacotherapy / Neurostimulation and AI-Augmented Cognitive Therapy
- 31. Personalized Medicine for Cognitive Impairments in PD
- 32. Ethical and Practical Challenges with Cognitive Enhancers
- 33. Unani Pharmacotherapy in the Management of Parkinson's disease: A Therapeutic Approach
- 34. Music therapy and its synergy with pharmacotherapy in Parkinson's Disease
- 35. Summary and Conclusion